Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients
- Conditions
- First Posted Date
- 2006-02-22
- Last Posted Date
- 2013-11-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT00294372
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site, Ulm, Germany
A Randomised, Double-blind, Crossover Study of Ba679BR Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- First Posted Date
- 2006-02-16
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 157
- Registration Number
- NCT00292448
- Locations
- 🇯🇵
Boehringer Ingelheim Investigational Site, Yokote, Akita, Japan
Efficacy and Tolerability CVI (A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial (CVI)
- Conditions
- First Posted Date
- 2006-02-16
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 202
- Registration Number
- NCT00292435
- Locations
- 🇨🇿
Neurology-geriatric Institute, Moravsky Beroun, Czech Republic
🇦🇹AKH Wien, Wien, Austria
🇦🇹LKH Graz, Graz, Austria
Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism
- Conditions
- Interventions
- First Posted Date
- 2006-02-14
- Last Posted Date
- 2014-06-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2564
- Registration Number
- NCT00291330
- Locations
- 🇺🇸
1160.53.01033 Boehringer Ingelheim Investigational Site, Sarasota, Florida, United States
🇺🇸1160.53.01046 Boehringer Ingelheim Investigational Site, Sarasota, Florida, United States
🇺🇸1160.53.01010 Boehringer Ingelheim Investigational Site, Marietta, Georgia, United States
Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 76
- Registration Number
- NCT00281567
- Locations
- 🇳🇱
Boehringer Ingelheim Investigational Site, Study chairs or principal investigators, Netherlands
Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2014-03-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1461
- Registration Number
- NCT00281580
- Locations
- 🇲🇽
1235.1.203, Col. Magdalena de las Salinas, Mexico
🇲🇽1235.1.208 "Ignacio Chávez", mexico DF, Mexico
🇲🇽1235.1.211 Obesidad Y Prevencion de Enfermedades, Mexico, D.F., Mexico
Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension
- Conditions
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1354
- Registration Number
- NCT00281593
- Locations
- 🇺🇸
1236.1.573 Boehringer Ingelheim Investigational Site, Long Beach, California, United States
🇺🇸1236.1.560 Boehringer Ingelheim Investigational Site, Encinitas, California, United States
🇺🇸1236.1.523 Boehringer Ingelheim Investigational Site, Buena Park, California, United States
A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA)
- Conditions
- First Posted Date
- 2006-01-20
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 226
- Registration Number
- NCT00279747
- Locations
- 🇦🇹
Univ.-Klinik für Kinder- und Jugendheilkunde Wien, Wien, Austria
🇦🇹Gottfried Preyersches Kinderspital d. Stadt Wien, Wien, Austria
🇧🇪UZ Gent, Gent, Belgium
Spiriva® Assessment of FEV1 (SAFE)
- Conditions
- First Posted Date
- 2006-01-16
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 914
- Registration Number
- NCT00277264
- Locations
- 🇨🇦
Penticton Regional Hospital, Penticton, British Columbia, Canada
🇨🇦220 Royal Avenue, New Westminster, British Columbia, Canada
🇨🇦825 Coxwell Avenue, Toronto, Ontario, Canada
Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients
- Conditions
- First Posted Date
- 2006-01-12
- Last Posted Date
- 2013-10-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 346
- Registration Number
- NCT00275457
- Locations
- 🇦🇹
Univ.-Klinik für Neurologie, Innsbruck, Austria
🇸🇪Boehringer Ingelheim Investigational Site, Örebro, Sweden
🇦🇹Confraternität Privatklinik, Wien, Austria